Lau IT, et al. – Efficacy and safety of new insulin glargine 300 units/mL (Gla–300) in the treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM) was assessed via a review of published clinical studies. Accumulated evidence pointed to the possibility of translating pharmacodynamic and pharmacokinetic properties of Gla–300 into clinical benefits in both T1DM and T2DM. Furthermore, data indicated that Gla–300 may offer therapuetic benefits for people initiating basal insulin, those requiring higher basal insulin doses, those with T1DM, and those who may be at increased risk for hypoglycemia, such as people with chronic kidney disease, the elderly, and those with cardiovascular comorbidities.

Methods

• Data was extracted from primary research articles on Gla-300, including pharmacodynamic, pharmacokinetic, and clinical studies.

Results

• Researchers noted that in pharmacodynamic and pharmacokinetic studies, Gla-300 showed a flatter time–action profile and longer duration of action than Gla-100.
• Findings revealed that noninferiority of Gla-300 versus Gla-100 for lowering of glycated hemoglobin was demonstrated in Phase III clinical studies covering a range of T1DM and T2DM patient populations.
• Data also highlighted that over 6–12 months of follow-up, Gla-300 consistently showed comparable glycemic efficacy with less hypoglycemia vs Gla-100, even during the first 8 weeks of treatment.
• Researchers observed that although titrated insulin doses were 11%–17% higher with Gla-300 vs Gla-100, changes in body weight were similar or favored Gla-300.